Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Clinical Utility of New Therapies for Benign Prostatic Bladder Outflow Obstruction

The Clinical Utility of New Therapies for Benign Prostatic Bladder Outflow Obstruction ]oumalof MANAGED CARE MANAGED CARE IN UROLOGY The clinical utility of new therapies for benign prostatic bladder outflow obstruction Simon St Clair Carter Consultant Urologist, Charing Cross Hospital INTRODUCTION an average of 4 days, significant bleeding is now a very rare complication and the TUR syndrome One of the greatest triumphs of minimally invasive (haemodilution by irrigant) is much less evident, surgery was the development of extracorporeal making the attraction of many new minirnally invasive shockwave lithotripsy for renal stones, and it was not techniques seem somewhat less obvious. With this surprising that urologists expected a similar in mind, it is important to constantly re-evaluate the technological revolution in the treatment of benign new treatments available and determine which patients prostatic bladder outflow obstruction (BOO). Such should be recommended to undergo these high hopes in the late 1980s and the early part of this procedures. decade led to the development of numerous commercial devices, mostly using heat as the therapeutic agent. Unfortunately, at the time these TECHNOLOGIES AVAILABLE technologies were introduced little information was The majority of novel device treatments use heat to available as to the best way of assessing outcome of alter the structure of the prostate http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Managed Care SAGE

The Clinical Utility of New Therapies for Benign Prostatic Bladder Outflow Obstruction

Carter, Simon St Clair
Journal of Managed Care , Volume 1 (1): 6 – Apr 1, 1997
Download PDF
6 pages

Loading next page...
 
/lp/sage/the-clinical-utility-of-new-therapies-for-benign-prostatic-bladder-CCB2FLT5wQ

References (25)

Publisher
SAGE
Copyright
© 1997 SAGE Publications
ISSN
1363-9595
DOI
10.1177/136395959700100108
Publisher site
See Article on Publisher Site

Abstract

]oumalof MANAGED CARE MANAGED CARE IN UROLOGY The clinical utility of new therapies for benign prostatic bladder outflow obstruction Simon St Clair Carter Consultant Urologist, Charing Cross Hospital INTRODUCTION an average of 4 days, significant bleeding is now a very rare complication and the TUR syndrome One of the greatest triumphs of minimally invasive (haemodilution by irrigant) is much less evident, surgery was the development of extracorporeal making the attraction of many new minirnally invasive shockwave lithotripsy for renal stones, and it was not techniques seem somewhat less obvious. With this surprising that urologists expected a similar in mind, it is important to constantly re-evaluate the technological revolution in the treatment of benign new treatments available and determine which patients prostatic bladder outflow obstruction (BOO). Such should be recommended to undergo these high hopes in the late 1980s and the early part of this procedures. decade led to the development of numerous commercial devices, mostly using heat as the therapeutic agent. Unfortunately, at the time these TECHNOLOGIES AVAILABLE technologies were introduced little information was The majority of novel device treatments use heat to available as to the best way of assessing outcome of alter the structure of the prostate

Journal

Journal of Managed Care – SAGE

Published: Apr 1, 1997

There are no references for this article.